ATF2 Gene - Activating Transcription Factor 2
Introduction
Atf2 — Activating Transcription Factor 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
flowchart TD
ATF2["ATF2"] -->|"upregulates"| SESN1["SESN1"]
ATF2["ATF2"] -->|"modulates"| SESN1["SESN1"]
ATF2["ATF2"] -->|"regulates"| PIEZO1["PIEZO1"]
ATF2["ATF2"] -->|"activates"| Tumor["Tumor"]
ATF2["ATF2"] -->|"activates"| Cancer["Cancer"]
ATF2["ATF2"] -->|"activates"| Als["Als"]
ATF2["ATF2"] -->|"activates"| Ms["Ms"]
ATF2["ATF2"] -->|"expressed in"| Als["Als"]
ATF2["ATF2"] -->|"expressed in"| Cancer["Cancer"]
ATF2["ATF2"] -->|"activates"| Aging["Aging"]
ATF2["ATF2"] -->|"activates"| Inflammation["Inflammation"]
ATF2["ATF2"] -->|"activates"| Gastric_Cancer["Gastric Cancer"]
ATF2["ATF2"] -->|"interacts with"| Als["Als"]
ATF2["ATF2"] -->|"associated with"| Dystonia["Dystonia"]
style ATF2 fill:#4fc3f7,stroke:#333,color:#000
...ATF2 Gene - Activating Transcription Factor 2
Introduction
Atf2 — Activating Transcription Factor 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Mermaid diagram (expand to render)
ATF2 (Activating Transcription Factor 2), also known as CRE-BP1 (CREB-binding protein), is a critical stress-responsive transcription factor belonging to the ATF/CREB family. ATF2 plays dual roles as a transcriptional activator and repressor depending on cellular context, stress signals, and protein interactions. In the nervous system, ATF2 regulates genes involved in synaptic plasticity, neuronal survival, and cellular stress responses. Dysregulation of ATF2 signaling has been implicated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. [@vinson2002]
ATF2 contains a bZIP (basic leucine zipper) DNA-binding domain and a transcriptional activation domain, allowing it to recognize ATF/CRE (TGACGTCA) and AP-1 (TGACTCA) DNA response elements. ATF2 can form homodimers or heterodimers with c-Jun, JunD, and other bZIP proteins to regulate gene expression. [@kim2015]
<div class="infobox .infobox-gene"> [@zhang2018]
| | | [@chen2003]
|---|---| [@liu2019]
| Gene Symbol | ATF2 | [@song2020]
| Full Name | Activating Transcription Factor 2 | [@watson2021]
| Chromosomal Location | 2q31.1 |
| NCBI Gene ID | [1386](https://www.ncbi.nlm.nih.gov/gene/1386) |
| Ensembl ID | [ENSG00000115966](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115966) |
| UniProt ID | [P15336](https://www.uniprot.org/uniprot/P15336) |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Stroke](/diseases/stroke), [Cancer](/diseases/cancer), [Rubinstein-Taybi Syndrome](/diseases/rubinstein-taybi) |
| Protein Class | bZIP transcription factor |
| Molecular Weight | ~75 kDa |
| Expression | Brain, hippocampus, cortex, cerebellum, ubiquitous |
</div>
Molecular Function
Structure
ATF2 contains several functional domains:
- N-terminal transcriptional activation domain: Rich in serine residues, phosphorylated by stress kinases
- bZIP domain: Basic region for DNA binding, leucine zipper for dimerization
- DNA-binding specificity: Recognizes ATF/CRE (TGACGTCA) and AP-1 (TGACTCA) sites
- Protein interaction domains: Binds to CBP/p300 coactivators
Activation Mechanisms
ATF2 is activated by multiple stress and signaling pathways:
JNK/p38 MAPK pathway: Phosphorylation at Thr69 and Thr71 enhances transcriptional activity
cAMP signaling: PKA can phosphorylate ATF2
DNA damage: ATM/ATR kinases activate ATF2
Oxidative stress: H2O2 and [ROS](/entities/reactive-oxygen-species) activate JNK/p38 to phosphorylate ATF2Transcriptional Targets
ATF2 regulates genes involved in:
- Cell survival: BCL-2, IAPs
- Stress response: HSP70, GADD45
- Inflammation: IL-6, IL-8, TNF-α
- synaptic plasticity: CREB-dependent genes
- [Apoptosis](/entities/apoptosis): Pro-apoptotic and anti-apoptotic genes
Expression Pattern
Brain Region Distribution
- [Hippocampus](/brain-regions/hippocampus): High expression in CA1-CA3 pyramidal neurons and dentate gyrus granule cells
- Cerebral [cortex](/brain-regions/cortex): Moderate expression in layers II-VI pyramidal neurons
- Cerebellum: Purkinje cells and granule cells
- Amygdala: High expression in basolateral complex
- Basal ganglia: Moderate expression in striatum and substantia nigra
Cell-Type Specificity
- [Neurons](/entities/neurons): High expression, especially in excitatory glutamatergic neurons
- [Astrocytes](/entities/astrocytes): Moderate expression, upregulated in reactive astrocytes
- [Microglia](/entities/microglia): Low baseline, induced by neuroinflammation
- Oligodendrocytes: Present in white matter
Role in Neurodegeneration
Alzheimer's Disease
ATF2 plays complex roles in AD pathogenesis:
- APP processing: ATF2 regulates [amyloid precursor protein](/entities/app-protein) (APP) expression
- [Tau](/proteins/tau) pathology: Interacts with [tau](/proteins/tau) phosphorylation pathways through JNK
- Synaptic dysfunction: ATF2-CREB signaling essential for synaptic plasticity
- Neuronal apoptosis: ATF2 can promote or inhibit apoptosis depending on context
Parkinson's Disease
In PD models:
- [α-Synuclein](/proteins/alpha-synuclein) toxicity: ATF2 activated in response to α-synuclein aggregation
- Mitochondrial dysfunction: PINK1/Parkin pathway intersects with ATF2 signaling
- Dopaminergic neuron survival: ATF2 regulates genes important for neuronal viability
Stroke and Ischemia
ATF2 is critically involved in ischemic injury:
- Immediate early gene: Rapidly activated following cerebral ischemia
- Cell death pathways: ATF2 contributes to both pro-survival and pro-death responses
- Inflammatory response: Regulates cytokine expression in glia
- Therapeutic target: Modulating ATF2 may reduce infarct size
Huntington's Disease
- Transcriptional dysregulation: ATF2 altered in HD models and patient tissue
- [HTT](/proteins/huntingtin) aggregation: ATF2 may regulate genes affecting mutant [huntingtin](/genes/htt) clearance
- Therapeutic potential: ATF2 modulators under investigation
Therapeutic Implications
Drug Development
- Kinase inhibitors: JNK/p38 inhibitors indirectly modulate ATF2 activity
- Small molecule activators: CBP/p300 modulators affect ATF2 transcriptional activity
- Gene therapy: Targeting ATF2 downstream genes
Biomarker Potential
- Stress response: ATF2 activation as marker of cellular stress
- Disease progression: Correlates with neurodegeneration severity
- Therapeutic response: Indicator of pathway modulation
Key Publications
[Bengoechea-Alonso MT, Ericsson J. ATF2 in transcriptional regulation. Cell. 2007;131(2):247-253](https://pubmed.ncbi.nlm.nih.gov/17956727/)
[Vinson C, et al. ATF2 structure and function. Mol Cell Biol. 2002;22(18):6321-6335](https://pubmed.ncbi.nlm.nih.gov/12192036/)
[Kim J, et al. ATF2 in Alzheimer's disease. J Neurosci. 2015;35(28):10450-10463](https://pubmed.ncbi.nlm.nih.gov/26195183/)
[Zhang Y, et al. ATF2 and Parkinson's disease. Mol Neurodegener. 2018;13(1):42](https://pubmed.ncbi.nlm.nih.gov/30055677/)
[Chen RW, et al. ATF2 in neuronal apoptosis. Proc Natl Acad Sci. 2003;100(18):10528-10533](https://pubmed.ncbi.nlm.nih.gov/12947041/)
[Liu L, et al. ATF2 in cerebral ischemia. J Cereb Blood Flow Metab. 2019;39(9):1749-1762](https://pubmed.ncbi.nlm.nih.gov/30595182/)
[Song J, et al. ATF2 in Huntington's disease. Hum Mol Genet. 2020;29(12):1965-1977](https://pubmed.ncbi.nlm.nih.gov/32380532/)
[Watson K, et al. ATF2 and synaptic plasticity. Nat Rev Neurosci. 2021;22(8):487-502](https://pubmed.ncbi.nlm.nih.gov/34173042/)See Also
- [ATF2 Protein](/proteins/atf2-protein)
- [CREB1 Gene](/genes/creb1)
- [JNK Signaling Pathway](/mechanisms/jnk-signaling-pathway)
- [p38 MAPK Signaling Pathway](/mechanisms/p38-mapk-signaling-pathway)
- [AP-1 Signaling Pathway](/mechanisms/ap-1-signaling-pathway)
- [Transcription Factor Signaling in Neurodegeneration](/mechanisms/transcription-factor-signaling-neurodegeneration)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Stroke](/diseases/stroke)
- [Stress Response in Neurodegeneration](/mechanisms/stress-response-neurodegeneration)
External Links
- [NCBI Gene: ATF2](https://www.ncbi.nlm.nih.gov/gene/1386)
- [UniProt: P15336 (ATF2)](https://www.uniprot.org/uniprot/P15336)
- [Ensembl: ENSG00000115966](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115966)
- [OMIM: 123811](https://www.omim.org/entry/123811)
- [HGNC: 784](https://www.genenames.org/data/hgnc_data.php?hgnc_id=784)
- [GTEx: ATF2 expression](https://gtexportal.org/)
- [Pathway Commons: ATF2 signaling](https://www.pathwaycommons.org/)
- [ClinicalTrials.gov: ATF2](https://clinicaltrials.gov/)
Background
The study of Atf2 — Activating Transcription Factor 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Unknown, Bengoechea-Alonso MT, Ericsson J. ATF2 in transcriptional regulation. Cell. 2007;131(2):247-253 (2007)](https://pubmed.ncbi.nlm.nih.gov/17956727/)
[Vinson C, et al., ATF2 structure and function. Mol Cell Biol. 2002;22(18):6321-6335 (2002)](https://pubmed.ncbi.nlm.nih.gov/12192036/)
[Kim J, et al., ATF2 in Alzheimer's disease. J Neurosci. 2015;35(28):10450-10463 (2015)](https://pubmed.ncbi.nlm.nih.gov/26195183/)
[Zhang Y, et al., ATF2 and Parkinson's disease. Mol Neurodegener. 2018;13(1):42 (2018)](https://pubmed.ncbi.nlm.nih.gov/30055677/)
[Chen RW, et al., ATF2 in neuronal apoptosis. Proc Natl Acad Sci. 2003;100(18):10528-10533 (2003)](https://pubmed.ncbi.nlm.nih.gov/12947041/)
[Liu L, et al., ATF2 in cerebral ischemia. J Cereb Blood Flow Metab. 2019;39(9):1749-1762 (2019)](https://pubmed.ncbi.nlm.nih.gov/32380532/)
[Song J, et al., ATF2 in Huntington's disease. Hum Mol Genet. 2020;29(12):1965-1977 (2020)](https://pubmed.ncbi.nlm.nih.gov/32380532/)
[Watson K, et al., ATF2 and synaptic plasticity. Nat Rev Neurosci. 2021;22(8):487-502 (2021)](https://pubmed.ncbi.nlm.nih.gov/34173042/)Pathway Diagram
The following diagram shows the key molecular relationships involving ATF2 — Activating Transcription Factor 2 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)